Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor NK Cell Therapy for AML
NCT05333705Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Natural Killer Cells in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Overall Survival at 2 years and Hematological Response Rate at 2 years. Status: unknown.
02
Drugs
Natural Killer Cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05333705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333705.